Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2013, Article ID 637086, 11 pages
http://dx.doi.org/10.1155/2013/637086
Research Article

Targeting the Vasculature of Colorectal Carcinoma with a Fused Protein of -tTF

1Department of Surgical Oncology, First Affiliated Hospital of Xiamen University, Xiamen, Fujian Province 361003, China
2Department of Hepatobiliary Surgery, Zhongshan Hospital of Xiamen University, Xiamen, Fujian Province 361004, China
3Cancer Research Center of Medical School, Xiamen University, Xiamen, Fujian Province 361102, China

Received 23 March 2013; Accepted 8 May 2013

Academic Editors: E. Z. Dajani and C. Rizzetto

Copyright © 2013 Zheng-jie Huang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. V. Klotz, M. E. Eichhorn, B. Schwarz et al., “Targeting the vasculature of visceral tumors: novel insights and treatment perspectives,” Langenbeck's Archives of Surgery, vol. 397, no. 4, pp. 569–578, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. F. Danhier, A. L. Breton, and V. Preat, “RGD-based strategies to target Alpha(v) Beta(3) integrin in cancer therapy and diagnosis,” Molecular Pharmaceutics, vol. 9, no. 11, pp. 2961–2973, 2012. View at Google Scholar
  3. E. Lorenzon, R. Colladel, E. Andreuzzi et al., “MULTIMERIN2 impairs tumor angiogenesis and growth by interfering with VEGF-A/VEGFR2 pathway,” Oncogene, vol. 31, pp. 3136–3147, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. D. W. Siemann, D. J. Chaplin, and M. R. Horsman, “Vascular-targeting therapies for treatment of malignant disease,” Cancer, vol. 100, no. 12, pp. 2491–2499, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. B. C. Baguley, “Antivascular therapy of cancer: DMXAA,” The Lancet Oncology, vol. 4, no. 3, pp. 141–148, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. V. Daubie, R. Pochet, S. Houard, and P. Philippart, “Tissue factor: a mini-review,” Journal of Tissue Engineering and Regenerative Medicine, vol. 1, no. 3, pp. 161–169, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. X. Chen, H. Lv, M. Ye et al., “Novel superparamagnetic iron oxide nanoparticles for tumor embolization application: preparation, characterization and double targeting,” International Journal of Pharmaceutics, vol. 426, no. 1-2, pp. 248–255, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Kessler, R. Bieker, T. Padró et al., “Inhibition of tumor growth by RGD peptide-directed delivery of truncated tissue factor to the tumor vasculature,” Clinical Cancer Research, vol. 11, no. 17, pp. 6317–6324, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Guan, B. Su, C. Ye, and Y. Lu, “Production of extracellular domain of human tissue factor using maltose-binding protein fusion system,” Protein Expression and Purification, vol. 26, no. 2, pp. 229–234, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Bieker, T. Kessler, C. Schwöppe et al., “Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience,” Blood, vol. 113, no. 20, pp. 5019–5027, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. X. Huang, G. Molema, S. King, L. Watkins, T. S. Edgington, and P. E. Thorpe, “Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature,” Science, vol. 275, no. 5299, pp. 547–550, 1997. View at Publisher · View at Google Scholar · View at Scopus
  12. X. Huang, W.-Q. Ding, J. L. Vaught et al., “Asoluble tissue factor-annexin V chimeric protein has both procoagulant and anticoagulant properties,” Blood, vol. 107, no. 3, pp. 980–986, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Ghose, B. Hubbard, and S. M. Cramer, “Binding capacity differences for antibodies and Fc-fusion proteins on protein A chromatographic materials,” Biotechnology and Bioengineering, vol. 96, no. 4, pp. 768–779, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Zitt, G. Untergasser, A. Amberger et al., “Dickkopf-3 as a new potential marker for neoangiogenesis in colorectal cancer: expression in cancer tissue and adjacent non-cancerous tissue,” Disease Markers, vol. 24, no. 2, pp. 101–109, 2008. View at Google Scholar · View at Scopus
  15. S. Goel, D. G. Duda, L. Xu et al., “Normalization of the vasculature for treatment of cancer and other diseases,” Physiological Reviews, vol. 91, no. 3, pp. 1071–1121, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. H. M. C. Shantha Kumara, S. T. Tohme, S. A. C. Herath et al., “Plasma soluble vascular adhesion molecule-1 levels are persistently elevated during the first month after colorectal cancer resection,” Surgical Endoscopy, vol. 26, no. 6, pp. 1759–1764, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. R. S. Saad, Y. L. Liu, G. Nathan, J. Celebrezze, D. Medich, and J. F. Silverman, “Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer,” Modern Pathology, vol. 17, no. 2, pp. 197–203, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. Z.-F. Su, G. Liu, S. Gupta, Z. Zhu, M. Rusckowski, and D. J. Hnatowich, “In vitro and in vivo evaluation of a technetium-99m-labeled cyclic RGD peptide as a specific marker of αvβ3 integrin for tumor imaging,” Bioconjugate Chemistry, vol. 13, no. 3, pp. 561–570, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. S. A. Mousa, S. Mohamed, E. J. Wexler, and J. S. Kerr, “Antiangiogenesis and anticancer efficacy of TA138, a novel αvβ3 antagonist,” Anticancer Research, vol. 25, no. 1, pp. 197–206, 2005. View at Google Scholar · View at Scopus
  20. H. Cai, Z. Li, C.-W. Huang, R. Park, and P. S. Conti, “64Cu labeled ambasar-RGD2 for micro-PET imaging of integrin αvβ3expression,” Current Radiopharmaceuticals, vol. 4, no. 1, pp. 68–74, 2011. View at Google Scholar · View at Scopus
  21. M. Haubitz and R. Brunkhorst, “Influence of a novel rapamycin analogon SDZ RAD on endothelial tissue factor and adhesion molecule expression,” Transplantation Proceedings, vol. 34, no. 4, pp. 1124–1126, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. B. A. Lwaleed and P. S. Bass, “Tissue factor pathway inhibitor: structure, biology and involvement in disease,” Journal of Pathology, vol. 208, no. 3, pp. 327–339, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. M. J. Fonseca, H. J. Haisma, S. Klaassen, M. H. Vingerhoeds, and G. Storm, “Design of immuno-enzymosomes with maximum enzyme targeting capability: effect of the enzyme density on the enzyme targeting capability and cell binding properties,” Biochimica et Biophysica Acta, vol. 1419, no. 2, pp. 272–282, 1999. View at Publisher · View at Google Scholar · View at Scopus
  24. K. Chen and X. Chen, “Integrin targeted delivery of chemotherapeutics,” Theranostics, vol. 1, pp. 189–200, 2011. View at Google Scholar
  25. J.-P. Xiong, T. Stehle, R. Zhang et al., “Crystal structure of the extracellular segment of integrin αVβ3 in complex with an Arg-Gly-Asp ligand,” Science, vol. 296, no. 5565, pp. 151–155, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. N. Papo, A. P. Silverman, J. L. Lahti, and J. R. Cochran, “Antagonistic VEGF variants engineered to simultaneously bind to and inhibit VEGFR2 and αvβ3 integrin,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 34, pp. 14067–14072, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. R. J. Kok, A. J. Schraa, E. J. Bos et al., “Preparation and functional evaluation of RGD-modified proteins as αvβ3 integrin directed therapeutics,” Bioconjugate Chemistry, vol. 13, no. 1, pp. 128–135, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. C. Schwöppe, T. Kessler, T. Persigehl et al., “Tissue-factor fusion proteins induce occlusion of tumor vessels,” Thrombosis Research, vol. 125, pp. S143–S150, 2010. View at Google Scholar · View at Scopus
  29. P. Hu, J. Yan, J. Sharifi, T. Bai, L. A. Khawli, and A. L. Epstein, “Comparison of three different targeted Tissue Factor fusion proteins for inducing tumor vessel thrombosis,” Cancer Research, vol. 63, no. 16, pp. 5046–5053, 2003. View at Google Scholar · View at Scopus
  30. Y. Maeshima, P. C. Colorado, and R. Kalluri, “Two RGD-independent αvβ3 integrin binding sites on tumstatin regulate distinct anti-tumor properties,” Journal of Biological Chemistry, vol. 275, no. 31, pp. 23745–23750, 2000. View at Publisher · View at Google Scholar · View at Scopus
  31. E. Kolvunen, B. Wang, and E. Ruoslahti, “Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins,” Bio/Technology, vol. 13, no. 3, pp. 265–270, 1995. View at Google Scholar · View at Scopus
  32. C. P. Carron, D. M. Meyer, V. W. Engleman et al., “Peptidomimetic antagonists of αvβ3 inhibit bone resorption by inhibiting osteoclast bone resorptive activity, not osteoclast adhesion to bone,” Journal of Endocrinology, vol. 165, no. 3, pp. 587–598, 2000. View at Google Scholar · View at Scopus
  33. P. L. Stewart, C. Y. Chiu, S. Huang et al., “Cryo-EM visualization of an exposed RGD epitope on adenovirus that escapes antibody neutralization,” EMBO Journal, vol. 16, no. 6, pp. 1189–1198, 1997. View at Publisher · View at Google Scholar · View at Scopus
  34. K. Temming, R. M. Schiffelers, G. Molema, and R. J. Kok, “RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature,” Drug Resistance Updates, vol. 8, no. 6, pp. 381–402, 2005. View at Publisher · View at Google Scholar · View at Scopus